Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cisplatin liposomal inhaled - Eleison Pharmaceuticals

Drug Profile

Cisplatin liposomal inhaled - Eleison Pharmaceuticals

Alternative Names: ILC; Inhaled cisplatin - Insmed; Inhaled lipid cisplatin; Inhaled lipid-complexed cisplatin (ILC); Lipid cisplatin complex

Latest Information Update: 12 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insmed
  • Developer Eleison Pharmaceuticals
  • Class Antineoplastics; Platinum complexes; Small molecules
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer metastases; Osteosarcoma
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 28 May 2021 Eleison Pharmaceuticals receives patent allowance for cisplatin liposomal inhaled in Canada
  • 28 May 2021 Eleison Pharmaceuticals plans a phase III trial for Small cell lung cancer (Inhalation) in 2021 or 2022
  • 28 Apr 2021 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer in Unknown (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top